Drug Topics
OCTOBER 28, 2024
Industry experts gathered to discuss pharmacy benefit managers, their current grasp on the drug supply chain, and how it all impacts independent pharmacies.
Pharmacy Times
OCTOBER 28, 2024
Champions for Vaccine Education, Equity, and Progress reported that the majority of pharmacists believe that it is important to prioritize vaccine development and distribution.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
PharmaVoice
OCTOBER 28, 2024
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
Fierce Healthcare
OCTOBER 28, 2024
Employers are concerned that rising healthcare costs could force them to rethink salary or wage increases, according to a new study. | Employers are concerned that rising healthcare costs could force them to rethink salary or wage increases, according to a new study.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Pharmacy Times
OCTOBER 28, 2024
Pharmacists play a key role when it comes to medication substitution, especially for interchangeable biosimilars where allowed by state law.
Fierce Healthcare
OCTOBER 28, 2024
As President Joe Biden prepares to leave office at the end of this year, he is taking final steps to push one of his signature domestic priorities to accelerate the fight against cancer. | As President Joe Biden prepares to leave office at the end of this year, he is taking final steps to push one of his signature domestic priorities to accelerate the fight against cancer.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Fierce Healthcare
OCTOBER 28, 2024
Elevance Health plans to acquire home health company CareBridge in a deal that's reportedly worth $2.7 billion. | Elevance Health plans to acquire home health company CareBridge, a deal that's reportedly worth $2.7 billion.
STAT
OCTOBER 28, 2024
A drug used to combat fungal infections in cancer patients comes with a big caveat — research shows the medicine can last twice as long as in people with obesity. This means chemotherapies may be less effective when interacting with the medicine, but some clinicians, and their patients, are unaware of that possibility. The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population.
PharmaVoice
OCTOBER 28, 2024
Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.
pharmaphorum
OCTOBER 28, 2024
MSD and Moderna start a third phase 3 trial of their V940 cancer vaccine, their second in early-stage lung cancer.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Pharmacy Times
OCTOBER 28, 2024
Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.
pharmaphorum
OCTOBER 28, 2024
Apple wins in patent infringement lawsuit with wearable maker Masimo, but fails to get the injunction on sales that it sought
Pharmaceutical Technology
OCTOBER 28, 2024
The enduring effects of redlining on public health, particularly on asthma prevalence, provide a striking example of how discriminatory housing policies from the 20th century continue to shape the well-being of marginalised communities affected by this practice today.
pharmaphorum
OCTOBER 28, 2024
Discover the latest advancements in cell therapy with the next generation of innovative treatments that are revolutionising healthcare. Explore the future of medicine today.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
The Guardian - Pharmaceutical Industry
OCTOBER 28, 2024
Prof Kelly Chibale says the world is failing to take advantage of African genetic diversity, and everyone could be losing out Africa has the greatest variety in human genes anywhere on the planet but the world is failing to capitalise on it, according one of the continent’s leading scientists, Prof Kelly Chibale, a man determined to change that. He believes the birthplace of humanity could hold the scientific key to its future.
pharmaphorum
OCTOBER 28, 2024
Novartis says Fabhalta shows sustained efficacy in rare disease C3G over 12 months, as it prepares for an FDA filing later this year
Drug Topics
OCTOBER 28, 2024
Researchers analyzed the lack of prevention and treatment options for managing drug-induced liver injury.
pharmaphorum
OCTOBER 28, 2024
Astellas confirmed today it will withdraw its EMA filing for avacincaptad pegol as a treatment for eye disorder geographic atrophy in the EU
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Drug Topics
OCTOBER 28, 2024
A conversation with Chelsee Jensen, PharmD, BCPS, senior pharmacy specialist at the Mayo Clinic.
pharmaphorum
OCTOBER 28, 2024
In a recent pharmaphorum webinar, we sat down with Melanie Walsh, Senior Director, IBD Franchise Customer Experience and Digital Innovation, at Takeda, to learn some tips for successful content transformation.
Drug Topics
OCTOBER 28, 2024
Don’t miss out on the latest pharmacy insights in the Drug Topics September/October issue.
pharmaphorum
OCTOBER 28, 2024
Discover how the healthcare industry is raising customer experience standards through meaningful real-person communication. Learn why this approach is vital for patient satisfaction and better outcomes.
Pharmaceutical Technology
OCTOBER 28, 2024
The US FDA has approved Iterum Therapeutics' NDA for ORLYNVAH to treat uncomplicated urinary tract infections (uUTIs).
STAT
OCTOBER 28, 2024
For several years, a rivalry has been brewing between two high-profile gene-editing companies. On one hand is Prime Medicine, built on prime editing, a technology out of David’s Liu lab at the Broad Institute for making small insertions, deletions, and single-letter changes to DNA. On the other is Tessera Therapeutics, a biotech launched by Flagship Pioneering, the VC behind Moderna, that has been, well, vague about precisely what it’s doing.
Pharmaceutical Technology
OCTOBER 28, 2024
China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western countries.
Fierce Pharma
OCTOBER 28, 2024
Earlier this year, EyePoint Pharmaceuticals’ drug-device combo Duravyu missed the mark in a non-proliferative diabetic retinopathy (NPDR) study, raising doubts about the product’s potential in seve | EyePoint released new diabetic macular edema data Monday that a Mizuho Securities analyst described as "very promising." The trial win provides a needed turnaround for the company's lead candidate Duravyu, which failed a study in non-proliferative diabetic retinopathy earlier this yea
Pharmacy Times
OCTOBER 28, 2024
Investigators found that electronic letter reminders were most effective for older individuals, those who were unvaccinated in the preceding season, those with cardiovascular disease, and those with diabetes.
STAT
OCTOBER 28, 2024
This story first appeared in The Readout newsletter. Sign up for The Readout and receive STAT’s award-winning biotech news delivered straight to your inbox. Hello! Today we take note of the antagonism between gene-editing players Prime Medicine and Tessera Therapeutics, consider the issue of whether the label should be updated on a Merck drug, and more.
Drug Topics
OCTOBER 28, 2024
With nearly 7 million women living in a health care desert, pharmacists can provide crucial reproductive care services.
Fierce Pharma
OCTOBER 28, 2024
Novartis and Apellis Pharmaceuticals have rolled out detailed data on iptacopan and pegcetacoplan, respectively, as they race for the prize in a type of rare kidney disease. | Novartis and Apellis dropped new data on their respective meds, iptacopan and pegcetacoplan, in the rare kidney disease C3 glomerulopathy. While Apellis' drug seems to have an efficacy edge based on a cross-trial comparison, Novartis may have gotten the jump by filing for approvals ahead of its competitor.
Drug Topics
OCTOBER 28, 2024
The NCPA 2024 Annual Convention and Expo runs through October 29, 2024, in Columbus, Ohio.
The Checkup by Singlecare
OCTOBER 28, 2024
Unlike some products, fish oil supplements are exactly what they say they are: oil extracted from the tissue of fatty, oily fish, such as mackerel, sardines, herring, anchovies, and salmon. The oil is then purified to be sold in liquid, capsule, or pill form. Many people believe it’s an easy way to supplement a healthy diet and treat certain health conditions.
Fierce Pharma
OCTOBER 28, 2024
While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.&nb | While Astellas’ Izervay and Apellis’ Syfovre battle for market share in geographic atrophy (GA) in the United States, both companies are struggling to reach patients in the indication in Europe.
Expert insights. Personalized for you.
220 
Let's personalize your content